Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
MWN-AI** Summary
Genenta Science S.p.A., now transitioning to Saentra Forge, is reshaping its strategic focus from biotechnology toward becoming a consolidator in critical sectors including biotech, defense, aerospace, and Italian national security technologies. This shift comes as the company seeks to explore new opportunities regarding its original biotechnology platform, particularly the investigational product Temferon. Professor Luigi Naldini and Bernhard Gentner originally developed this platform, and Genenta is collaborating with DC Advisory to identify potential partners for its advancement. However, as of now, no active discussions have emerged regarding strategic partnerships for Temferon.
CEO Pierluigi Paracchi, a co-founder, remains committed to Genenta, having increased his shareholding during trading windows. He emphasized that founder-scientists will not sell their shares until Temferon receives third-party validation, reflecting confidence in the underlying science despite uncertainties surrounding its development.
The strategic pivot toward Saentra Forge aims to aggregate promising scale-ups in sectors vital for national security. The initiative is focused on retaining and developing Italy’s significant industrial technology assets, emphasizing capital infusion, structural support, and access to public markets via Nasdaq, all to cultivate national champions in critical industries.
With this evolution, Saentra Forge positions itself to actively engage with the market and foster long-term shareholder value through disciplined execution and selective acquisitions. The company underscores the unique value Italy possesses in technology and industrial capabilities, reiterating its commitment to keeping that value within the country.
Amidst significant market uncertainties, Genenta is poised for transformative growth, drawing on its existing scientific portfolio while branching into essential strategic domains. Shareholders will be kept informed of ongoing developments as the company navigates this new chapter.
MWN-AI** Analysis
As Genenta Science S.p.A. transitions into Saentra Forge, it's clear that a strategic pivot towards becoming an industrial aggregator in biotechnology and national-security-related technologies marks a significant evolution for the company. This transformation aligns with broader market trends where strategic consolidators thrive by identifying high-potential investments across several vital sectors, including defense and aerospace—fields increasingly essential in today’s geopolitical climate.
While the exploration of partnerships for its biotechnology platform, particularly Temferon, faces challenges, the ongoing engagement with DC Advisory suggests Saentra Forge is laying the groundwork for future collaborations that capitalize on Italy's robust technological landscape. Investors should monitor how these negotiations progress since successful partnerships may enhance both the scientific credibility and marketability of Temferon.
The commitment demonstrated by the founder-scientists, particularly CEO Pierluigi Paracchi, to bolster their positions amidst uncertain market responses serves as a compelling indicator of confidence in the company's fundamentals. Their belief in the long-term potential of Temferon and the industrial aggregator model could reassure investors wary of short-term volatility.
However, the uncertainties outlined in financial disclosures, including ongoing clinical trials and legal challenges, could pose risks to revenue generation and share price stability. It’s imperative for investors to remain vigilant about these factors while assessing the overall strategic direction.
Entering sectors like biotechnology and cybersecurity not only diversifies Saentra Forge's portfolio but also aligns with increasing governmental support for national security initiatives. Therefore, investors should consider Saentra Forge's potential as an emerging player—monitoring its capital acquisitions and strategic alignments could yield substantial opportunities for growth.
In conclusion, with a disciplined execution plan and a focus on high-quality acquisitions, Saentra Forge is in a position to enhance shareholder value sustainably, should it successfully navigate its transitional challenges.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, today announced that, with respect to its biotechnology platform, Genenta has been and continues to be actively engaged with DC Advisory to explore potential collaboration opportunities for the further development of its original biotechnology platform, which originated from research conducted by founder-scientists, Professor Luigi Naldini and Bernhard Gentner. To date, DC Advisory has not identified, and the Company is not in any active discussions with, potential strategic partners regarding Temferon or its biotechnology platform. Genenta nevertheless intends to continue pursuing potential collaboration opportunities in light of the quality of the underlying science and the preliminary clinical data previously generated.
“As a co-founder, I have never sold my shares in Genenta; in fact, I have increased my position by purchasing ADSs during open trading windows,” said Pierluigi Paracchi, CEO of Genenta. “The founder-scientists are currently holders of Genenta’s ordinary shares and Genenta opposes any sale of shares by the founder-scientists unless and until Temferon receives meaningful third-party validation. Given the current uncertainty surrounding the future development of Temferon, the founder-scientists have been aware of Genenta’s need to broaden its strategic path, even if they have not fully shared that view.
We are building Genenta into an industrial aggregator operating in some of the most strategically sensitive sectors of the modern economy — biotech, defense, aerospace, and cybersecurity. Think of us as a forge: we identify the most promising scale-ups in sectors that matter for national security, and we provide them with capital, structure, indirect access to the U.S. public markets through our Nasdaq listing, and the industrial capabilities needed to help them become national champions. We are pursuing this strategy not in spite of the market, but ahead of it. Italy produces extraordinary technology and industrial value. Too often, however, it fails to retain them. We believe that this value creation should remain here. Above all, this strategic evolution is intended to serve the best interests of our shareholders, and we remain fully focused on creating long-term shareholder value through disciplined execution and the selective acquisition of high-quality industrial assets.”
About: Genenta Science (Nasdaq: GNTA), is evolving into a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security-regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity.
Forward-Looking Statements. Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech, the funding provided by the recently acquired Mandatory Convertible Bond, the Phase 1/2a clinical trial for newly diagnosed GBM patients with uMGMT-GBM or any related studies, as well as Genenta’s ability to establish partnerships and fund its research and development plans. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in Genenta's Annual Report on Form 20-F for the year ended December 31, 2024, and Genenta's material disclosures on Form 6-K dated October 10, 2025, both filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of the date of this announcement, and Genenta undertakes no duty to update such information except as required under applicable law. This press release discusses product candidates that are under preclinical or clinical evaluation and that have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. Until finalized in a clinical study report, clinical trial data presented herein remain subject to adjustment as a result of clinical site audits and other review processes. No representation is made as to the safety or effectiveness of these product candidates or the use for which such product candidates are being studied. Temferon™ is an investigational product candidate for which the effectiveness and safety have not been established. In addition, Temferon™ is not approved for use in any jurisdiction.
Genenta Science Media
Tiziana Pollio, Mobile: +39 348 23 15 143
email: tiziana.pollio@genenta.com
1 The adoption of the corporate name Saentra Forge S.p.A. remains subject to shareholder approval.
FAQ**
How does the transformation of Genenta Science S.p.A. (GNTA) into Saentra Forge impact its existing biotechnology platform and ongoing clinical trials, especially concerning Temferon?
What specific strategies is Genenta Science S.p.A. (GNTA) implementing to attract potential collaboration opportunities with strategic partners for its biotechnology platform?
Can you elaborate on the rationale behind Genenta Science S.p.A. (GNTA)'s decision to pursue an industrial consolidation strategy focused on sectors like biotech and national security?
What are the potential risks and uncertainties associated with the transition of Genenta Science S.p.A. (GNTA) to Saentra Forge, particularly in terms of financial stability and regulatory approvals?
**MWN-AI FAQ is based on asking OpenAI questions about Genenta Science S.p.A. (NASDAQ: GNTA).
NASDAQ: GNTA
GNTA Trading
14.77% G/L:
$0.7002 Last:
11,214 Volume:
$0.66 Open:
